leadf
logo-loader
viewZelira Therapeutics Ltd
(
ASX:ZLDOTCQB:ZLDAF
)

Zelira Therapeutics partners with SprinJene to launch first over-the-counter CBD toothpaste in the US

Discussions are ongoing to access SprinJene’s global distribution networks in France, Russia, the UK, Singapore, Ukraine, China, Morocco, UAE, Saudi Arabia and Sudan Shoprite. 

Zelira Therapeutics Ltd - Zelira Therapeutics launches its first over-the-counter CBD toothpaste in the US in partnership with SprinJene
The CBD toothpaste is the first of several scientifically formulated oral health care products to launch under the Zelira Oral Care subsidiary

Zelira Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G), in partnership with SprinJene®, a leader in natural oral care products, has launched its first over-the-counter (OTC) proprietary CBD toothpaste in the US.

The Zelira-SprinJene® CBD product will be distributed in the US through SprinJene’s existing distribution channels including retail stores such as Bed Bath & Beyond, Central Market, Sprouts, Lassen’s, Haggens, VitaCos and e-commerce platforms such as Amazon. 

Discussions are ongoing to access SprinJene’s global distribution networks in France, Russia, the UK, Singapore, Ukraine, China, Morocco, United Arab Emirates, Saudi Arabia and Sudan Shoprite.

Improving head-to-toe health

Zelira chief executive officer and managing director USA markets Dr Oludare Odumosu said: “Zelira is thrilled to enter the national oral care market alongside a company that values the harmony of nature and science as much as we do.

“SprinJene® was an early adopter of nature-based oral care and they are continuing to innovate now by recognising the effectiveness of CBD and other cannabinoids in improving our head-to-toe health.”

SprinJene CEO and founder Dr Sayed Ibrahim said: “The SprinJene® brand is built on harnessing the power of natural ingredients to protect and improve our oral health, and CBD with its inherent anti-inflammatory, antibacterial and homeostatic properties are shown to be powerful tools in that fight.

“Research is showing that cannabinoids will be a major part of the future of oral1-3 and Zelira was the perfect partner for SprinJene® to set the industry standard in broad-spectrum, hemp-derived oral care formulations.”

The CBD toothpaste is the first of several scientifically formulated oral health care products to launch under the Zelira Oral Care subsidiary.

Proprietary CBD toothpaste

The CBD toothpaste is a proprietary formulation developed by Zelira and SprinJene’s Dr Ibrahim.

The product is the first of several scientifically formulated, hemp-derived, oral care products containing cannabinoids, including broad-spectrum CBD, that will be created and launched under the Zelira Oral Care subsidiary that has partnered with the SprinJene® brand.

Research shows that incorporating CBD into oral/dental care results in health benefits, including naturally eliminating decay-causing bacteria, reducing gum inflammation, restoring pH balance and increasing remineralisation, reducing bone loss associated with gum disease, and helping to improve overall health.

The Zelira-SprinJene® CBD toothpaste uses broad-spectrum, THC-free CBD distillate derived from hemp, which provides Zelira-SprinJene® users with the full benefits of a wide array of cannabinoids, with no psychoactive effects.

Quick facts: Zelira Therapeutics Ltd

Follow
ASX:ZLD

Price: 0.043 AUD

Market Cap: $51.18 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Zelira Therapeutics enters German market through an exclusive cannabis...

Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) (ASX:ZLD) (OTCQB:ZLDAF) Managing Director Dr Oludare Odumosu tells Proactive the group has expanded into Europe via the large and growing German cannabinoid-based medicines market through an exclusive distribution agreement with Adjupharm GmbH, a...

2 days, 13 hours ago

2 min read